Lipidor and Cadila Pharmaceuticals, one of the largest pharmaceutical manufacturing groups in India, have entered into a collaboration agreement for the commercialisation of a sprayable anti-psoriatic product
The sprayable product consists of the generic Vitamin D analogue, Calcipotriol, formulated with Lipidor´s patented lipid-based drug delivery technology, Akvano and targets patients with mild to moderate psoriasis.
Under the collaboration agreement, Cadila Pharmaceuticals will conduct a Phase III programme in India starting in 2016.
“We are very pleased with our collaboration with Cadila Pharmaceuticals, which will enable us to bring this important psoriasis product to the market”, said Anders Carlsson, CEO of Lipidor.
“Cadila Pharmaceuticals’ partnership with Lipidor AB evolves from its vision to partner with leading global research institutions to find novel, innovative and affordable solutions for unmet medical needs. Psoriasis is a condition with high prevalence in India and globally”, said Rajiv Modi, chairman and managing director, Cadila Pharmaceuticals.